Ensysce Biosciences posts video updates from IASP World Congress on Pain

Ensysce Biosciences has made available two video segments from its August 8th symposium at the International Association for the Study of Pain 2024 World Congress on Pain in Amsterdam, Netherlands. The Company’s symposium emphasized opioid use worldwide, the current landscape for treating severe pain, including post-surgical and cancer pain treatment, and discussed Ensysce’s innovative new class of opioid drug products. The discussion allowed for feedback and questions from experts in attendance facilitating proper introduction and explanation of the differentiated Ensysce approach and the possible needs from countries outside the United States for these unique opioids. Two short videos from the session have been posted to Media / Science Center page on the Company’s website. Dr. William Schmidt, Chief Medical Officer of Ensysce explains the government support the Company has received from both the National Institutes of Health and the FDA, as well as described how the profile of Ensysce’s lead agent, PF614, checks all the categories of what could be perceived as an ideal pain product.